AIMS: @entity1255 (Hcy) has emerged as an important risk factor for @entity731 . Elevated levels in chronic dialysis @entity1 may contribute to high vascular mortality, but little is known about levels of related @entity1522 in this group. In an observational study in the clinical setting we sought to document these. METHODS: In 114 hemodialysis @entity1 pre-dialysis total plasma @entity1255 , @entity2186 and red blood cell (RBC) @entity1501 concentrations were measured. In a subgroup of @entity1 (n = 42), other plasma @entity1522 were measured pre- and post-dialysis. All @entity1 were routinely taking oral @entity1501 supplements (1.2 mg per week). RESULTS: Elevated @entity1255 concentrations were found in all @entity1 (geometric mean 33.1 umol/l, range 13.8 - 69.2 umol/l, laboratory reference range (RR) 3-13 umol/l). RBC @entity1501 levels were high (1223 +/- 54.5 nmol/l mean +/- SE, RR 300 - 710 nmol/l) and inversely related to pre-dialysis plasma Hcy (r = -0.44, p < 0.001). Hcy levels were not related to @entity2186 levels. A history of @entity455 was not associated with higher concentrations of Hcy. Hcy clearance on dialysis was substantial (mean Hcy reduction 33 +/- 14%). While plasma @entity1853 levels were normal, @entity563 levels were significantly lower than the reference range (59.3 +/- 2.39 umol/l (mean +/- SE, RR 70 - 195 umol/l)) and directly related to levels of @entity2228 (r = 0.52, p < 0.001). @entity2228 levels were within normal range. Although overall levels were low, higher @entity563 levels were related to elevated @entity1255 (r = 0.42, p < 0.01). Dialytic loss of @entity2228 , @entity563 and @entity1853 was moderate. CONCLUSION: An inverse association between RBC @entity1501 and @entity1255 levels extended to 3 times the upper limit of normal for @entity1501 , suggesting a role for high dose @entity1501 supplementation in the treatment of @entity177 related @entity3562 . Low @entity563 levels are expected as it is primarily synthesized in the kidney. The direct relationship between @entity563 and @entity1255 is consistent with the reported lack of effect of @entity563 supplements on high Hcy levels.

Relationships between @entity1255 and related @entity1522 in chronic hemodialysis XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid', 'folate'] @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease'] @entity2228 :: ('CHEBI:57305', 'Chemical') :: ['glycine', 'Glycine'] @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine', 'Homocysteine'] @entity2186 :: ('MESH:D014805', 'Chemical') :: ['vitamin B12'] @entity1853 :: ('MESH:D008715', 'Chemical') :: ['methionine'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal-failure'] @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic disease'] @entity3562 :: ('MESH:D020138', 'Disease') :: ['hyperhomocysteinemia']
@entity1 :: (9606,Species) :: ['patients']
